Dr. Martens Plc

As of March 31, 2026, Dr. Martens Plc carries a market capitalization of 60.22B, placing it among publicly traded companies globally. Its enterprise value stands at 81.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dr. Martens Plc's next confirmed earnings release is scheduled for November 26, 2026.

As of March 31, 2026, Dr. Martens Plc has 956.62M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Dr. Martens Plc maintains a current ratio of 2.61, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Dr. Martens Plc's stock has declined approximately 29.56% over the past 52 weeks. The 50-day moving average sits at 71.58, while the 200-day moving average is 70.10.

As of March 31, 2026, Dr. Martens Plc holds 18.03B in cash and equivalents against 39.35B in total debt, resulting in a net debt position of 6.94B. Total book value stands at 36.15B, with working capital of 25.72B providing operational flexibility.